BioFocus DPI, a Galapagos Company, today announced two major enhancements to its ADMEnsa high-quality ADME optimization services. In addition to opening a US West Coast unit to better serve its customers, it has also significantly upgraded the proprietary ADMEnsa Interactive software through improved data analysis and visualization. These capabilities enable the efficient design, identification and prioritization of compounds at all stages of the drug discovery process by indicating the optimal balance of properties critical to a compound’s success.

Located in San Diego, the new ADMEnsa group builds on BioFocus DPI’s track record of success in drug discovery by providing flexible, rapid ADME optimization services. Taking a consultative approach, they aim to extract the greatest value from all ADME and DMPK2 data and advise on the next steps to move projects forward effectively. The West Coast ADMEnsa team will be headed by Dr. Shamsi Raeissi, who brings with her extensive drug discovery and preclinical development knowledge gained through over 15 years of industrial experience with Bayer Health Care, Pfizer, Sugen and Rhone-Poulenc Rorer.

“The BioFocus DPI ADMEnsa and medicinal chemistry groups in San Diego will provide a versatile service dedicated to delivering balanced leads and preclinical candidates for our clients,” said Dr. Shamsi Raeissi.

In addition to the expanded laboratory service, BioFocus DPI has upgraded its ADMEnsa Interactive software suite to include a range of enhanced data analysis and visualization tools. Coupled closely to the suite’s unique probabilistic scoring and chemical space analyses, these new capabilities create an even richer decision-support environment. The package’s unique compound prioritization framework means that in silico predictions can be integrated with data from other sources such as in vitro and in vivo experiments to aid effective decision making.

“While ADMEnsa has always provided rapid, high-quality ADME services to a global customer base, the establishment of our West Coast facility will enhance the personalized service we provide to our customers in North America and the Asia Pacific region.” said Dr. Matt Segall, Senior Director of BioFocus DPI’s ADMEnsa division. “The upgrade of ADMEnsa Interactive further establishes its position as the most comprehensive platform, combining in silico modeling and interactive decision support for drug discovery scientists.”

For more information on accessing the ADMEnsa services or licensing ADMEnsa Interactive, visit www.admensa.com

About BioFocus DPI

As the service business unit for Galapagos NV, an integrated drug discovery company, BioFocus DPI aims to expand our partners’ drug pipelines by accelerating the gene-to-candidate discovery process. We achieve this by offering a biologically-focused discovery platform with three key differentiators:

• target discovery in human primary cells
• hit discovery using focused chemogenomic libraries as well as diverse compound collections
• predictive drug discovery tools

Through a proprietary adenoviral platform with human full-length cDNA and shRNA constructs, we are able to rapidly identify and validate disease-modifying drug targets. Once a target has been selected, our focused small-molecule libraries, large diversity collection and natural product libraries can be applied to generate hits. These hits can then be further optimized through our predictive drug discovery tools applied in medicinal and computational chemistry as well as through our assay development, high throughput screening, and ADME optimization - thereby progressing our partners’ discovery programs. BioFocus DPI has over 300 employees and operates facilities across Europe and the US. For more information about BioFocus DPI, please visit www.biofocusdpi.com.